喘息治療薬の世界市場：画期的医薬品の市場機会及び商用化...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Executive Summary 4
2.1 Biologics Growing in Prominence in Asthma Treatment 4
2.2 Market Landscape to Grow in Diversity over Coming Years 4
2.3 Deals Landscape Offers Significant Investment Opportunities for First-in-Class Products 4

3 The Case for Innovation in Asthma 5
3.1 Growing Number of Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-Class Product Developments Remain Attractive 6
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 7
3.6 GBI Research Report Guidance 8

4 Clinical and Commercial Landscape 9
4.1 Disease Overview 9
4.1.1 Epidemiology 9
4.1.2 Etiology 10
4.1.3 Disease Pathophysiology 10
4.1.4 Disease Symptoms 11
4.1.5 Diagnosis 11
4.1.6 Assessment of Disease Severity 12
4.1.7 Treatment 14
4.1.8 Treatment Algorithm 14
4.2 Overview of Marketed Products 16
4.2.1 Quick-Relief Medication 17
4.2.2 ICSs for the Maintenance Treatment of Asthma 17
4.2.3 ICS/LABA Combination Therapy for the Maintenance Treatment of Asthma 18
4.2.4 Add-on Therapy to ICS or ICS/LABA Therapies for the Maintenance Treatment of Asthma 19
4.2.5 Conclusion 20

5 Assessment of Pipeline Product Innovation 21
5.1 Asthma Pipeline by Phase, Molecule Type and Therapeutic Target 21
5.2 Comparative Distribution of Programs between the Asthma Market and Pipeline by Molecular Target 26
5.3 First-in-Class Pipeline Programs Targeting Novel Molecule Targets 26

6 Signaling Network, Disease Causation and Innovation Alignment 31
6.1 The Complexity of Signaling Networks in Asthma 31
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 32
6.3 First-in-Class Target Matrix Assessment 34

7 First-in-Class Target and Pipeline Program Evaluation 36
7.1 Pipeline Programs Targeting Leukotriene A4 Hydrolase 36
7.2 Pipeline Programs Targeting P-selectin 38
7.3 Pipeline Programs Targeting Spleen Tyrosine Kinase 39
7.4 Pipeline Programs Targeting Prostaglandin D2 Receptor 2 41
7.5 Pipeline Programs Targeting OX40 Ligand 43
7.6 Pipeline Programs Targeting Interleukin-33 44
7.7 Pipeline Programs Targeting Interleukin-10 45
7.8 Pipeline Programs Targeting Mast Stem Cell Growth Factor Receptor 47
7.9 Pipeline Programs Targeting Bradykinin B1 Receptor 48
7.10 Conclusion 49

8 Deals and Strategic Consolidations 51
8.1 Industry-Wide First-in-Class Deals 51
8.2 Licensing Deals 53
8.3 Co-development Deals 57
8.4 First-in-Class Programs not Involved in Licensing or Co-Development Deals 59

9 Appendix 62
9.1 References 62
9.2 Abbreviations 66
9.2.1 Expert Panel Validation 67
9.3 Contact Us 67
9.4 Disclaimer 67